GeoVax Labs, Inc., a clinical-stage biotechnology company, has issued a stark warning about the urgent need for the United States to enhance its pandemic preparedness and biodefense capabilities. With the global spread of Mpox and the emergence of immune-evasive COVID-19 variants, the company stresses the importance of modernizing the nation's countermeasure infrastructure and reducing reliance on foreign vaccine supplies.
David Dodd, Chairman and CEO of GeoVax, highlighted the growing threats posed by Mpox and COVID-19, including the spread of Clade I Mpox strains and the dominance of the NB.1.8.1 ('Nimbus') COVID-19 variant. Dodd pointed out the vulnerabilities in the current system, such as the Strategic National Stockpile's dependence on a single foreign supplier for Mpox/smallpox vaccines, which is unable to meet global demand.
GeoVax is advancing two vaccine candidates to address these threats: GEO-MVA for Mpox/smallpox and GEO-CM04S1, a next-generation COVID-19 vaccine. These candidates are supported by Phase 2 clinical data and aim to provide robust, durable immune protection, particularly for immunocompromised individuals.
The company's call to action comes amid bipartisan support for strengthening the U.S.'s biodefense posture. Policymakers are advocating for legislation to prioritize domestic manufacturing and procurement of pandemic countermeasures, aligning with GeoVax's mission to deliver American-made solutions.
GeoVax's plea for immediate investment in domestic vaccine production and diversification of the national stockpile underscores the critical window of opportunity to prepare for future health emergencies before they escalate into full-blown crises.
